Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Behavioral Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$7,938,286

623 payments

Through program year 2025, Behavioral Clinical Research Inc is reported as receiving $7,938,286 in research payments, across 623 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $108,719 10
2024 Research $1,651,449 90
2023 Research $4,170,844 177
2022 Research $162,440 80
2021 Research $312,960 76
2020 Research $849,175 98
2019 Research $682,700 92

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $6,174,891 256 payments
  2. Indivior Inc. $920,244 116 payments
  3. Sumitomo Pharma America, Inc. $501,453 95 payments
  4. Sage Therapeutics, Inc. $165,031 46 payments
  5. Neurocrine Biosciences, Inc. $70,302 41 payments
  6. Tolmar, Inc. $40,652 25 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $28,489 24 payments
  8. ITI, Inc. $12,216 1 payment
  9. Biohaven Pharmaceuticals, Inc. $7,443 10 payments
  10. Hoffmann-La Roche Limited $6,637 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $4,621,019 119 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $1,361,846 90 payments
  3. A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of SUBLOCADE at Alternative Injection Locations in Adults $714,570 16 payments
  4. A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects with Schizophrenia $329,519 22 payments
  5. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $192,025 47 payments
  6. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $184,046 96 payments
  7. An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication $104,091 12 payments
  8. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $78,062 17 payments
  9. Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $62,917 36 payments
  10. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Sage-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia $45,180 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record